Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evorpacept - ALX Oncology

X
Drug Profile

Evorpacept - ALX Oncology

Alternative Names: ALX-148; CD47/SIRPa-blocking Agent ALX 148; SIRPa Variant ALX 148

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexo Therapeutics
  • Developer ALX Oncology; Eli Lilly and Company; Merck & Co; Merck Sharp & Dohme; Quantum Leap Healthcare Collaborative; University of California; Zymeworks
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gastric cancer
  • Phase II Colorectal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Phase I/II Acute myeloid leukaemia; HER2 positive breast cancer; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Breast cancer; Urogenital cancer
  • Preclinical Multiple myeloma

Most Recent Events

  • 02 Jun 2024 Efficacy and adverse event data from a phase I trial in Urogenital cancer released by ALX Oncology
  • 30 May 2024 Preclinical trials in Multiple myeloma in USA (IV) (ALX oncology pipeline, May 2024)
  • 09 Apr 2024 Pharmacodynamics data from preclinical study in Solid tumours released by ALX Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top